Current Liabilities decreased faster than Jupiter Neurosciences Inc 's Cash & cash equivalent, this led to improvement in Jupiter Neurosciences Inc 's Quick Ratio to 0.47, Quick Ratio remained below Jupiter Neurosciences Inc average.

Within Major Pharmaceutical Preparations industry 395 other companies have achieved higher Quick Ratio than Jupiter Neurosciences Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 2693, from total ranking in the first quarter 2026 at 2735.

Explain Quick Ratio?
How much Cash & cash equivalents JUNS�s has?
What are JUNS�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

JUNS Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	25.91 %	255.8 %	276.43 %	-55.66 %	-55.48 %
Y / Y Cash & cash equivalent Change	-18.97 %	-12.7 %	0.53 %	285985.77 %	6490.34 %
Quick Ratio MRQ	0.47	0.35	0.51	0.29	0.73
JUNS's Total Ranking	# 2693	# 2735	# 2314	# 2594	# 1731
Seq. Current Liabilities Change	-51.65 %	-8.83 %	192.78 %	-2.43 %	36.61 %
Seq. Cash & cash equivalent Change	-35.59 %	-37.65 %	423.54 %	-61.46 %	-30.6 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 396
Healthcare Sector	# 749
Overall Market	# 2693

Quick Ratio Statistics
High	Average	Low
1.92	0.63	0
(Dec 31 2024)		(Sep 30 2024)

Financial Statements
Jupiter Neurosciences Inc 's Current Liabilities	$ 3 Millions	Visit JUNS's Balance sheet
Jupiter Neurosciences Inc 's Cash & cash equivalent	$ 2 Millions	Visit JUNS's Balance sheet
Source of JUNS's Sales		Visit JUNS's Sales by Geography

Cumulative Jupiter Neurosciences Inc 's Quick Ratio

JUNS's Quick Ratio for the trailling 12 Months

JUNS Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	64.04 %	25.25 %	6.89 %	-22.04 %	108.88 %
Y / Y Cash & cash equivalent TTM Growth	0.52 %	34.58 %	139.53 %	31472.44 %	29213.96 %
Quick Ratio TTM	0.42	0.46	0.63	1.01	0.69
Total Ranking TTM	# 4075	# 3677	# 3122	# 3299	# 3174
Seq. Current Liabilities TTM Growth	3.48 %	33.65 %	60.51 %	-26.11 %	-20.99 %
Seq. Cash & cash equivalent TTM Growth	-4.07 %	-3.78 %	0.22 %	8.66 %	28.44 %

Quick ratio ranking by company, industry and sector >> Back to JUNS Financial Strength Comparisons >> Go to Compare JUNS Quick Ratio to its Competitors

On the trailing twelve months basis Due to drop in Current Liabilities in the Q2 2026 to $3.25 millions, cumulative Quick Ratio decreased to 0.42 below the Jupiter Neurosciences Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 438 other companies have achieved higher Quick Ratio than Jupiter Neurosciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3677 to 4075.

Explain Quick Ratio?
How much Cash & cash equivalents JUNS�s has?
What are JUNS�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 439
Healthcare Sector	# 903
Within the Market	# 4075

trailing twelve months Quick Ratio Statistics
High	Average	Low
1	0.6	0.41
(Sep 30 2025)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Elite Pharmaceuticals Inc	1.28	$ 39.032 Millions	$ 30.442 Millions
Ani Pharmaceuticals Inc	1.27	$ 360.212 Millions	$ 283.655 Millions
Pmgc Holdings Inc	1.25	$ 19.126 Millions	$ 15.329 Millions
Petros Pharmaceuticals inc	1.23	$ 3.489 Millions	$ 2.845 Millions
Nature s Sunshine Products inc	1.20	$ 82.503 Millions	$ 68.745 Millions
Phathom Pharmaceuticals Inc	1.19	$ 182.478 Millions	$ 153.777 Millions
Compass Pathways Plc	1.18	$ 433.720 Millions	$ 367.285 Millions
Geovax Labs Inc	1.17	$ 3.163 Millions	$ 2.712 Millions
Actuate Therapeutics Inc	1.16	$ 4.426 Millions	$ 3.805 Millions
Apimeds Pharmaceuticals US, Inc.	1.16	$ 8.278 Millions	$ 7.166 Millions
Emergent Biosolutions Inc	1.14	$ 139.700 Millions	$ 122.800 Millions
Turn Therapeutics Inc	1.14	$ 9.958 Millions	$ 8.764 Millions
Ionis Pharmaceuticals Inc	1.11	$ 350.065 Millions	$ 315.638 Millions
Oramed Pharmaceuticals Inc	1.00	$ 16.091 Millions	$ 16.044 Millions
Inmed Pharmaceuticals Inc	1.00	$ 2.240 Millions	$ 2.235 Millions
Nkarta Inc	1.00	$ 24.958 Millions	$ 24.924 Millions
Inovio Pharmaceuticals Inc	1.00	$ 36.700 Millions	$ 36.678 Millions
Jazz Pharmaceuticals Plc	0.98	$ 2,199.800 Millions	$ 2,239.400 Millions
Akebia Therapeutics Inc	0.97	$ 155.548 Millions	$ 160.865 Millions
Syndax Pharmaceuticals Inc	0.95	$ 342.883 Millions	$ 360.284 Millions
Nurix Therapeutics Inc	0.94	$ 67.840 Millions	$ 72.020 Millions
Theriva Biologics inc	0.94	$ 11.337 Millions	$ 12.111 Millions
Geron Corporation	0.92	$ 64.781 Millions	$ 70.331 Millions
Zomedica Corp	0.84	$ 7.605 Millions	$ 9.002 Millions
Cocrystal Pharma Inc	0.83	$ 2.169 Millions	$ 2.616 Millions
Harrow Inc	0.82	$ 83.889 Millions	$ 102.171 Millions
Cue Biopharma Inc	0.82	$ 17.414 Millions	$ 21.218 Millions
Zoetis Inc	0.81	$ 1,676.000 Millions	$ 2,061.000 Millions
Organogenesis Holdings Inc	0.81	$ 46.097 Millions	$ 56.963 Millions
Bridgebio Pharma Inc	0.81	$ 720.160 Millions	$ 890.648 Millions

Date modified: 2026-09-26T07:43:07+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.